HCA Healthcare's Anticipated Quarterly Earnings: A Deep Dive

HCA Healthcare (NYSE:HCA) is a leading hospital chain in the United States, known for its exceptional management and robust financial performance. The company provides essential healthcare services and has a strong presence in the sector. HCA's financial health and strategic initiatives make it an attractive option for investors looking to diversify their portfolios.

On July 28, 2025, Ben Hendrix from RBC Capital set a price target of $401 for HCA. At that time, HCA's stock was priced at $334.29, suggesting a potential increase of approximately 19.96%. As of now, the stock price has risen to $337.33, reflecting a $3.01 increase or about 0.90%. This upward trend indicates positive market sentiment towards HCA.

HCA's recent financial results show strong revenue and earnings per share (EPS) growth. The company is actively repurchasing shares and maintaining manageable debt levels, which supports strong shareholder returns. With a 16x multiple on 2025 EPS, HCA's fair value is estimated at $416 per share, implying a potential total return of 25% from current levels.

The stock has traded between $331.70 and $338.17 today, with a market capitalization of approximately $81.15 billion. Over the past year, HCA's stock has reached a high of $417.14 and a low of $289.98. The current valuation and financial performance highlight HCA Healthcare as a strong buy, as noted by Ben Hendrix's price target and the company's ongoing strategic efforts.

HCA Healthcare (NYSE:HCA) reported second-quarter earnings that beat expectations, prompting the hospital operator to raise its full-year guidance.

Adjusted EPS came in at $6.84, topping estimates by $0.57, while revenue reached $18.61 billion, exceeding the $18.49 billion consensus.

Same-facility admissions rose 1.8%, and equivalent admissions increased 1.7% year-over-year. Emergency room visits rose 1.3%, while inpatient and outpatient surgeries dipped 0.3% and 0.6%, respectively. Revenue per equivalent admission grew 4.0% from the prior year.

HCA now expects 2025 revenue between $74.0 billion and $76.0 billion, up from its earlier range of $72.8 billion to $75.8 billion. Adjusted EBITDA is forecast at $14.7 billion to $15.3 billion, and diluted EPS is projected at $25.50 to $27.00, up from the previous $24.05 to $25.85 range.

HCA Healthcare, Inc. (NYSE:HCA) is a prominent player in the healthcare sector, known for operating hospitals, surgery centers, and emergency care facilities across the United States. The company is dedicated to providing high-quality patient care and has been investing in technology and staff to enhance its services. HCA's strategic focus on adapting to regulatory changes and expanding its operations has contributed to its strong market position.

On April 25, 2025, HCA reported its first-quarter earnings, showcasing a robust financial performance. The company achieved an earnings per share (EPS) of $6.45, surpassing the estimated $5.75. This marks a significant improvement from the previous year's $5.36 per share, highlighting an 11.79% earnings surprise. HCA has consistently outperformed consensus EPS estimates over the past four quarters, demonstrating its financial strength.

HCA's revenue for the quarter reached $18.32 billion, slightly exceeding the forecasted $18.26 billion. This represents a 0.08% increase over the Zacks Consensus Estimate and a notable rise from $17.34 billion in the same period last year. The company has surpassed consensus revenue estimates in three of the last four quarters, underscoring its strong performance in the Zacks Medical - Hospital industry.

During the Q1 2025 earnings conference call, CEO Sam Hazen and CFO Mike Marks discussed HCA's financial results and strategic direction. The call included participation from analysts and investors from major financial institutions like Mizuho Securities, Deutsche Bank, UBS, and Bank of America. The discussion likely covered operational highlights and future outlook, providing valuable insights into HCA's market position.

HCA's financial metrics further illustrate its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 14.34, indicating how the market values its earnings. Its price-to-sales ratio is about 1.13, reflecting investor willingness to pay per dollar of sales. Despite a negative debt-to-equity ratio of -18.10, HCA maintains a current ratio of approximately 1.08, suggesting its ability to cover short-term liabilities with short-term assets.

HCA Healthcare, Inc. (NYSE:HCA) is a prominent player in the healthcare sector, known for operating hospitals, surgery centers, and emergency care facilities across the United States. The company is dedicated to providing high-quality patient care and has been investing in technology and staff to enhance its services. HCA's strategic focus on adapting to regulatory changes and expanding its operations has contributed to its strong market position.

On April 25, 2025, HCA reported its first-quarter earnings, showcasing a robust financial performance. The company achieved an earnings per share (EPS) of $6.45, surpassing the estimated $5.75. This marks a significant improvement from the previous year's $5.36 per share, highlighting an 11.79% earnings surprise. HCA has consistently outperformed consensus EPS estimates over the past four quarters, demonstrating its financial strength.

HCA's revenue for the quarter reached $18.32 billion, slightly exceeding the forecasted $18.26 billion. This represents a 0.08% increase over the Zacks Consensus Estimate and a notable rise from $17.34 billion in the same period last year. The company has surpassed consensus revenue estimates in three of the last four quarters, underscoring its strong performance in the Zacks Medical - Hospital industry.

During the Q1 2025 earnings conference call, CEO Sam Hazen and CFO Mike Marks discussed HCA's financial results and strategic direction. The call included participation from analysts and investors from major financial institutions like Mizuho Securities, Deutsche Bank, UBS, and Bank of America. The discussion likely covered operational highlights and future outlook, providing valuable insights into HCA's market position.

HCA's financial metrics further illustrate its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 14.34, indicating how the market values its earnings. Its price-to-sales ratio is about 1.13, reflecting investor willingness to pay per dollar of sales. Despite a negative debt-to-equity ratio of -18.10, HCA maintains a current ratio of approximately 1.08, suggesting its ability to cover short-term liabilities with short-term assets.

• HCA Healthcare, Inc. (NYSE:HCA) reported an EPS of $6.22, exceeding both the estimated $6.13 and the Zacks Consensus Estimate of $5.97.
• The company's revenue for the quarter was $18.29 billion, slightly above the estimated $18.23 billion.
• HCA's financial metrics reveal a price-to-earnings (P/E) ratio of 13.96 and an earnings yield of approximately 7.17%.

HCA Healthcare, Inc. (NYSE:HCA) is a prominent player in the healthcare sector, providing a wide range of medical services across the United States. The company operates hospitals and outpatient facilities, offering comprehensive healthcare services. HCA competes with other major healthcare providers like Tenet Healthcare and Community Health Systems.

On January 24, 2025, HCA reported earnings per share (EPS) of $6.22, surpassing the estimated $6.13. This performance also exceeded the Zacks Consensus Estimate of $5.97 per share, showcasing HCA's ability to outperform market expectations. Compared to the previous year's same quarter EPS of $5.90, this indicates a positive growth trajectory for the company.

HCA's revenue for the quarter reached $18.29 billion, slightly above the estimated $18.23 billion. The company reported $18.3 billion in revenue for the fourth quarter of 2024, with net income attributable to HCA amounting to $1.4 billion, or $5.63 per diluted share. This figure includes an estimated unfavorable impact of $0.60 per diluted share due to Hurricanes Helene and M.

HCA's financial metrics provide insight into its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 13.96, indicating how the market values its earnings. Its price-to-sales ratio is about 1.17, reflecting investor willingness to pay per dollar of sales. The enterprise value to sales ratio is around 1.78, showing the company's total valuation relative to its sales.

HCA's financial structure is unique, with a negative debt-to-equity ratio of -20.57, which may suggest specific accounting treatments. The company maintains a current ratio of approximately 1.12, indicating its ability to cover short-term liabilities with short-term assets. HCA's earnings yield is about 7.17%, providing a measure of return on investment for shareholders.

• HCA Healthcare, Inc. (NYSE:HCA) reported an EPS of $6.22, exceeding both the estimated $6.13 and the Zacks Consensus Estimate of $5.97.
• The company's revenue for the quarter was $18.29 billion, slightly above the estimated $18.23 billion.
• HCA's financial metrics reveal a price-to-earnings (P/E) ratio of 13.96 and an earnings yield of approximately 7.17%.

HCA Healthcare, Inc. (NYSE:HCA) is a prominent player in the healthcare sector, providing a wide range of medical services across the United States. The company operates hospitals and outpatient facilities, offering comprehensive healthcare services. HCA competes with other major healthcare providers like Tenet Healthcare and Community Health Systems.

On January 24, 2025, HCA reported earnings per share (EPS) of $6.22, surpassing the estimated $6.13. This performance also exceeded the Zacks Consensus Estimate of $5.97 per share, showcasing HCA's ability to outperform market expectations. Compared to the previous year's same quarter EPS of $5.90, this indicates a positive growth trajectory for the company.

HCA's revenue for the quarter reached $18.29 billion, slightly above the estimated $18.23 billion. The company reported $18.3 billion in revenue for the fourth quarter of 2024, with net income attributable to HCA amounting to $1.4 billion, or $5.63 per diluted share. This figure includes an estimated unfavorable impact of $0.60 per diluted share due to Hurricanes Helene and M.

HCA's financial metrics provide insight into its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 13.96, indicating how the market values its earnings. Its price-to-sales ratio is about 1.17, reflecting investor willingness to pay per dollar of sales. The enterprise value to sales ratio is around 1.78, showing the company's total valuation relative to its sales.

HCA's financial structure is unique, with a negative debt-to-equity ratio of -20.57, which may suggest specific accounting treatments. The company maintains a current ratio of approximately 1.12, indicating its ability to cover short-term liabilities with short-term assets. HCA's earnings yield is about 7.17%, providing a measure of return on investment for shareholders.